Avelox instructions for use

Please note that before buying the drug Avelox, you must carefully read the instructions for use, methods of application and dosage, as well as other useful information on the drug Avelox.

On the site "Encyclopaedia of Diseases" you will find all the necessary information: instructions for use, dosage, contraindications, as well as reviews of patients who have already used this medication.

Avelox - Composition and form of release

Avelox coated tablets:

1 tablet contains moxifloxacin (in the form of hydrochloride) 400 mg
in the box 1 blister for 5 or 7 pcs., or in a box 2 blisters for 5 pcs.

Avelox solution for infusion:

1 vial contains moxifloxacin (in the form of hydrochloride) 400 mg
other ingredients: sodium chloride, sodium hydroxide, hydrochloric acid, water d / and.
250 ml -1 bottle in the box.

Avelox solution for infusion:

1 package contains moxifloxacin (in the form of hydrochloride) 400 mg
other ingredients: sodium chloride, sodium hydroxide, hydrochloric acid, water d / and.
250 ml - polyolefin bags (1) - polyethylene bags, laminated with foil (12) in a box.

Avelox - Pharmacological action

Avelox is a fairly effective antibacterial drug of a group of fluoroquinolones. Has a bactericidal effect. The mechanism of action is due to the inhibition of bacterial topoisomerases II and IV, which leads to a violation of the synthesis of DNA from a microbial cell. In vitro the drug is active against a wide range of gram-negative and gram-positive bacteria, mycoplasmas, chlamydia, ureaplasma, legionella, anaerobic pathogens. Effective against bacteria resistant to beta-lactam and macrolide antibiotics.

Gram-positive aerobic bacteria are sensitive to Avelox: Streptococcus pneumoniae (including strains resistant to penicillin and macrolides), Streptococcus pyogenes (group A), Streptococcus milled, Streptococcus mitis, Streptococcus agalactiae, Streptococcus dysgalactiae, Staphylococcus aureus (including methicillin-sensitive strains), Staphylococcus cohnii, Staphylococcus epidermidis (including methicillin-sensitive strains), Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus, Staphylococcus simulans, Corynebacterium diphtheriae; Gram-negative aerobic bacteria: Haemophilus influenzae (including strains producing and non-producing beta-lactamases), Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis (including strains producing and non-producing beta-lactamases), Escherichia coli, Enterobacter cloacae, Bordetella pertussis, Klebsiella oxytoca, Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter intermedius, Enterobacter sakazaki, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Providencia rettgeri, Providencia stuartii; anaerobic bacteria: Bacteroides distasonis, Bacteroides eggerthii, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicronron, Bacteroides uniformis, Fusobacterium spp., Porphyromonas spp. (including Porphyromonas anaerobius, Porphyromonas asaccharolyticus, Porphyromonas magnus), Prevotella spp., Propionibacterium spp., Clostridium perfringens, Clostridium ramosum; as well as Chlamydia pneumoniae, Mycoplasma pneumoniae, Legionella pneumophila, Coxiella burnettii. Moxifloxacin is less active against Pseudomonas aeruginosa, Pseudomonas fluorescens, Burkholderia cepacia, Stenotrophomonas maltophilia.

Mechanisms that lead to the development of resistance to penicillins, cephalosporins, aminoglycosides, macrolides and tetracyclines do not interfere with the antibacterial activity of moxifloxacin. Cross-resistance between these groups of antibacterial drugs and moxifloxacin is not noted. The overall frequency of development of resistance is very low (10-7-10-10). Resistance to moxifloxacin develops slowly by multiple mutations.

There are cases of cross-resistance to quinolones. Nevertheless, some gram-positive and anaerobic microorganisms resistant to other quinolones are sensitive to moxifloxacin.

Avelox - Indications for use

Infectious-inflammatory diseases caused by microorganisms sensitive to the preparation:

- exacerbation of chronic bronchitis;

- community-acquired pneumonia;

- Acute sinusitis;

- infections of the skin and soft tissues.

Avelox - Dosage and Administration

Avelox is prescribed inside and IV in 400 mg 1 time / day.

The duration of treatment with oral and / or induction is determined by the severity of the infection and the clinical effect and is as follows: with exacerbation of chronic bronchitis 5 days, with community-acquired pneumonia 7-14 days (first IV, then inside), with acute sinusitis and infections skin and soft tissues - 7 days.

The duration of treatment with Avelox can be up to 14 days.

Avelox - Side effects

On the part of the gastrointestinal tract: abdominal pain, nausea, diarrhea, vomiting, dyspepsia , a violation of liver function tests. Significantly less were other side effects.

From the cardiovascular system: tachycardia , peripheral edema, high blood pressure and heartbeat, chest pain.

From the musculoskeletal system: pain in the back, arthralgia, myalgia.

From the nervous system: insomnia, dizziness , nervousness, drowsiness, anxiety, tremor, paresthesia, confusion, depression , asthenia, a feeling of general discomfort.

Allergic reactions: rash, itching, hives .

From the sense organs: amblyopia, taste disorders.

From the genitourinary system: vaginal candidiasis , vaginitis .

Avelox - Contraindications

- Pregnancy ;

- lactation (breastfeeding);

- children and adolescence under 18;

- hypersensitivity to moxifloxacin and other components of the drug.

With caution - for diseases of the central nervous system (including diseases suspected of involving the central nervous system), predisposing to the occurrence of convulsive seizures and lowering the threshold of convulsive readiness, prolongation of the QT interval, hypokalemia , bradycardia , acute myocardial ischemia, with simultaneous reception with drugs, prolonging the QT interval, and antiarrhythmic agents of Class I and III, severe hepatic insufficiency.

Avelox - Special instructions

The drug is prescribed with caution against a background of antiarrhythmic drugs of class Ia and II, corticosteroids, as well as patients with a history of CNS disease, predisposing to the occurrence of convulsive seizures, severe violations of the liver function, syndrome of prolongation of the QT interval.

Avelox - Interaction with other medications

Co-administration of Avellox and antacids, minerals and vitamin-mineral complexes inwardly can disrupt the absorption of moxifloxacin, due to the formation of chelate complexes with polyvalent cations contained in these preparations, and, consequently, to reduce the concentration of moxifloxacin in the blood plasma. In this regard, drugs containing calcium, magnesium, aluminum, iron, should be taken at least 4 hours before or 2 hours after oral administration of Avelox.

Pharmaceutical interaction

Infusion solution of moxifloxacin is incompatible with the following infusion solutions: sodium chloride solution 10%, sodium chloride solution 20%, sodium bicarbonate solution 4.2%, sodium bicarbonate solution 8.4%.

Analogues of Avelox

Analogues for the active substance: Plevilox, Vigamox, Moxifloxacin, Moxin, Mossimak.

Analogues on the pharmacological group: Abaktal, Alzipro, Vigamoks, Gatispan, Glevo, Zanotsin, Zofloks, Quipro, Levoleth R, Levofloxacin, Lomefloxacin, Microflox, Nevigramon, Negram, Nolycin, Norbaktin, Norfloxacin, Oflox, Ofloxacin, Oflotsid, Palin, Pefloxacin, Recipro, Siflox, Tavanic, Uniflox, Factive, Floracid, Haileflex, Ciprobai, Ciprolet, Ciprofloxacin, Cyphran, Eleflox, Unicpeph, Utibid

Storage conditions

Store in a dry place, protected from light, out of reach of children, at a temperature of no higher than 25 ° C.

Shelf life of the tablets is 5 years; solution - 3 years. After dilution with compatible solvents, Avelox's solution remains stable for 24 hours at room temperature.